XBiotech Inc (XBIT) - Total Assets
Based on the latest financial reports, XBiotech Inc (XBIT) holds total assets worth $150.08 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check XBiotech Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
XBiotech Inc - Total Assets Trend (2012–2025)
This chart illustrates how XBiotech Inc's total assets have evolved over time, based on quarterly financial data. Check XBIT cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
XBiotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
XBiotech Inc's total assets of $150.08 Million consist of 84.6% current assets and 15.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.7% |
| Accounts Receivable | $360.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how XBiotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XBiotech Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XBiotech Inc's current assets represent 84.6% of total assets in 2025, an increase from 51.5% in 2012.
- Cash Position: Cash and equivalents constituted 83.7% of total assets in 2025, up from 49.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
XBiotech Inc Competitors by Total Assets
Key competitors of XBiotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
XBiotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.01 | 11.56 | 120.51 |
| Quick Ratio | 16.01 | 11.56 | 120.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $119.02 Million | $159.46 Million | $325.18 Million |
XBiotech Inc - Advanced Valuation Insights
This section examines the relationship between XBiotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.48 |
| Asset Growth Rate (YoY) | -24.6% |
| Total Assets | $150.08 Million |
| Market Capitalization | $72.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values XBiotech Inc's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: XBiotech Inc's assets decreased by 24.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for XBiotech Inc (2012–2025)
The table below shows the annual total assets of XBiotech Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $150.08 Million | -24.62% |
| 2024-12-31 | $199.09 Million | -12.14% |
| 2023-12-31 | $226.62 Million | -7.92% |
| 2022-12-31 | $246.10 Million | -10.57% |
| 2021-12-31 | $275.18 Million | -22.21% |
| 2020-12-31 | $353.74 Million | -56.70% |
| 2019-12-31 | $816.88 Million | +1742.09% |
| 2018-12-31 | $44.34 Million | -29.58% |
| 2017-12-31 | $62.97 Million | -6.08% |
| 2016-12-31 | $67.05 Million | -38.69% |
| 2015-12-31 | $109.36 Million | +75.88% |
| 2014-12-31 | $62.18 Million | +461.52% |
| 2013-12-31 | $11.07 Million | +30.75% |
| 2012-12-31 | $8.47 Million | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more